Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunization against poliomyelitis: risk/benefit/cost in a changing context.

J Salk

    Developments in Biological Standardization
    |January 1, 1979
    PubMed
    Summary

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Liver-on-chip model and application in predictive genotoxicity and mutagenicity of drugs.

    Mutation research. Genetic toxicology and environmental mutagenesis·2024
    Same author

    The immunology of new generation vaccines.

    Immunology today·2014
    Same author

    Impact of the filling status of the bladder and rectum on their integral dose distribution and the movement of the uterus in the treatment planning of gynaecological cancer.

    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·1999
    Same author

    [Comparison of different 3-dimensional irradiation techniques in local radiotherapy of prostatic carcinoma].

    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·1999
    Same author

    Viral load, CD4 percentage, and delayed-type hypersensitivity in subjects receiving the HIV-1 immunogen and antiviral drug therapy.

    Journal of clinical immunology·1996
    Same author

    Initial studies on active immunization of HIV-infected subjects using a gp120-depleted HIV-1 Immunogen: long-term follow-up.

    Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association·1996

    This study examines the benefits and risks of killed and live poliovirus vaccines, considering poliomyelitis prevalence in developed and developing nations. It analyzes vaccine-associated risks and discusses eradication strategies for long-term safety.

    Area of Science:

    • Immunology
    • Public Health
    • Epidemiology

    Background:

    • Poliomyelitis remains a global health concern, necessitating effective vaccination strategies.
    • The choice between inactivated poliovirus vaccine (IPV) and oral poliovirus vaccine (OPV) involves complex benefit-risk considerations.
    • Poliovirus prevalence varies significantly between developed and developing countries, influencing vaccine strategy.

    Purpose of the Study:

    • To compare the relative risks and efficacy of IPV and OPV in diverse epidemiological settings.
    • To identify and quantify risk factors associated with poliovirus vaccination.
    • To discuss strategies for the ultimate eradication of poliovirus.

    Main Methods:

    • Review of existing data on poliovirus vaccine efficacy and adverse events.
    Keywords:
    AmericasCost Benefit AnalysisCost EffectivenessDelivery Of Health CareDeveloped CountriesDeveloping CountriesDiseasesEvaluationEvaluation IndexesEvaluation MethodologyHealthHealth ServicesImmunization--costMedicineNorth AmericaNorthern AmericaPreventive MedicinePrimary Health CareQuantitative EvaluationResearch MethodologyUnited StatesVaccination--administraction and dosageVaccination--costViral Diseases--prevention and control

    Related Experiment Videos

  • Analysis of risk factors, including vaccine-derived poliovirus accessing the central nervous system (CNS) and vaccine failure.
  • Comparative assessment of risks in developed versus developing countries.

    • Main Results:

    • Data illustrate varying degrees of vaccine-associated risks in different global contexts.
    • Efficacy and risk profiles differ between IPV and OPV, impacting their suitability.
    • Specific risk factors, such as CNS invasion by vaccine virus, are quantified.

    Conclusions:

    • The optimal polio immunization strategy must account for local poliomyelitis prevalence and specific vaccine risks.
    • Eradication of wild and vaccine-derived poliovirus is the ultimate goal for eliminating associated risks.
    • Ongoing surveillance and tailored vaccination approaches are crucial for global polio elimination.